Hypoxia-ameliorated photothermal manganese dioxide nanoplatform for reversing doxorubicin resistance
Drug resistance is a huge hurdle in tumor therapy. Tumor hypoxia contributes to chemotherapy resistance by inducing the hypoxia-inducible factor-1α (HIF-1α) pathway. To reduce tumor hypoxia, novel approaches have been devised, providing significant importance to reverse therapeutic resistance and im...
Saved in:
Published in | Frontiers in pharmacology Vol. 14; p. 1133011 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
24.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Drug resistance is a huge hurdle in tumor therapy. Tumor hypoxia contributes to chemotherapy resistance by inducing the hypoxia-inducible factor-1α (HIF-1α) pathway. To reduce tumor hypoxia, novel approaches have been devised, providing significant importance to reverse therapeutic resistance and improve the effectiveness of antitumor therapies. Herein, the nanosystem of bovine serum albumin (BSA)-templated manganese dioxide (MnO
) nanoparticles (BSA/MnO
NPs) loaded with doxorubicin (DOX) (DOX-BSA/MnO
NPs) developed in our previous report was further explored for their physicochemical properties and capacity to reverse DOX resistance because of their excellent photothermal and tumor microenvironment (TME) response effects. The DOX-BSA/MnO
NPs showed good biocompatibility and hemocompatibility. Meanwhile, DOX-BSA/MnO
NPs could greatly affect DOX pharmacokinetic properties, with prolonged circulation time and reduced cardiotoxicity, besides enhancing accumulation at tumor sites. DOX-BSA/MnO
NPs can interact with H
O
and H
in TME to form oxygen and exhibit excellent photothermal effect to further alleviate hypoxia due to MnO
, reversing DOX resistance by down-regulating HIF-1α expression and significantly improving the antitumor efficiency in DOX-resistant human breast carcinoma cell line (MCF-7/ADR) tumor model. The hypoxia-ameliorated photothermal MnO
platform is a promising strategy for revering DOX resistance. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Yuning Zhang,First Hospital of Jilin University, China These authors have contributed equally to this work This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology Leli Zeng, Sun Yat-sen University, China Reviewed by: Yuan Tang, University of Toledo, United States |
ISSN: | 1663-9812 1663-9812 |
DOI: | 10.3389/fphar.2023.1133011 |